Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in February.

It is the first time that a PrEP trial has been shown to prevent any HIV infections from slipping through the net, according to Gilead, and showed a subcutaneous injection with lenacapavir every ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...

Lenacapavir is a long-acting pre-exposure prophylaxis (PrEP) product, a treatment that works by stopping HIV from getting into the body and making copies of itself. Unlike oral PrEP treatments ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Lenacapavir is a long-acting pre-exposure prophylaxis (PrEP) product, a treatment that works by stopping HIV from getting into the body and making copies of itself. Unlike oral PrEP treatments ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...

In March, the companies released 24-week data from the Phase 2 study of the combination of islatravir and lenacapavir for HIV infection. At 24 weeks, the investigational combination maintained a ...

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

We need nothing less than disruptive action to ensure everyone who wants access to affordable lenacapavir can get it.

Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio. Read why I ...